White House officials during the Trump administration pressured U.S. regulators to reauthorize a COVID-19 treatment and not impose certain guidance regarding emergency authorization requirements for COVID-19 vaccines, according to emails published by a House of Representatives panel on Aug. 24.
Officials sent a blitz of messages in 2020 to Dr. Stephen Hahn, the director of the U.S. Food and Drug Administration (FDA) at the time, regarding hydroxychloroquine, including requests to reimplement emergency use authorization for the drug.
